Earendil Labs closed a $787 million financing to advance an AI‑driven biologics pipeline spanning autoimmune and oncology programs. The round included Dimension, Luminous Ventures and Sanofi among backers and funds will accelerate multiple programs toward clinical testing and expand R&D capacity, the company said. Earendil claims more than 40 programs generated by its AI platform and lists nearly 20 pipeline candidates; one program targeting IBD is positioned for Phase 2. The company signaled ambitions for a Hong Kong IPO and emphasized the capital will allow parallel progression of multiple candidates rather than sequential de‑risking. The financing underscores investor appetite for AI‑first biotech plays that couple computational design with biologic modalities, and further cements partnerships between big pharma and AI‑native startups.